NZ532635A
(en)
|
2001-11-13 |
2007-05-31 |
Univ Pennsylvania |
A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
|
EP1453547B1
(en)
|
2001-12-17 |
2016-09-21 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
CN1856576B
(en)
|
2003-09-30 |
2011-05-04 |
宾夕法尼亚州立大学托管会 |
Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
|
ES2442225T3
(en)
|
2004-04-28 |
2014-02-10 |
The Trustees Of The University Of Pennsylvania |
Immunization regime with suppressed adenovirus priming in E4 and potentiation of adenovirus suppressed in E1
|
EP1742668B1
(en)
|
2004-04-28 |
2011-02-09 |
The Trustees of The University of Pennsylvania |
Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations
|
CN104293835B
(en)
|
2005-04-07 |
2017-07-04 |
宾夕法尼亚大学托管会 |
The method for strengthening function of gland related viral vector
|
WO2007120542A2
(en)
|
2006-03-30 |
2007-10-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Aav capsid library and aav capsid proteins
|
US20070274908A1
(en)
|
2006-04-07 |
2007-11-29 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to adenoassociated virus-phage particles
|
EP2018421B1
(en)
|
2006-04-28 |
2012-12-19 |
The Trustees of the University of Pennsylvania |
Scalable production method for aav
|
WO2008027084A2
(en)
*
|
2006-04-28 |
2008-03-06 |
The Trustees Of The University Of Pennsylvania |
Modified aav vectors having reduced capsid immunogenicity and use thereof
|
EP2191001B1
(en)
|
2007-04-09 |
2016-06-08 |
University of Florida Research Foundation, Inc. |
Raav vector compositions having tyrosine-modified capsid proteins and methods for use
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
EP2019143A1
(en)
*
|
2007-07-23 |
2009-01-28 |
Genethon |
CNS gene delivery using peripheral administration of AAV vectors
|
EP2058401A1
(en)
*
|
2007-10-05 |
2009-05-13 |
Genethon |
Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
|
WO2009108274A2
(en)
*
|
2008-02-26 |
2009-09-03 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for adeno-associated virus (aav) with hi loop mutations
|
US8632764B2
(en)
|
2008-04-30 |
2014-01-21 |
University Of North Carolina At Chapel Hill |
Directed evolution and in vivo panning of virus vectors
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
ES2634118T3
(en)
|
2009-02-11 |
2017-09-26 |
The University Of North Carolina At Chapel Hill |
Modified virus vectors and methods to manufacture and use them
|
CN102439157B
(en)
|
2009-04-30 |
2015-09-16 |
宾夕法尼亚大学托管会 |
Comprise the target conducting airways cell composition of adeno associated virus construct
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
US9133479B2
(en)
*
|
2009-06-03 |
2015-09-15 |
Cedars-Sinai Medical Center |
Effective vector platform for gene transfer and gene therapy
|
WO2011041502A1
(en)
|
2009-10-01 |
2011-04-07 |
The Trustees Of The University Of Pennsylvania |
Aav vectors expressing sec1o for treating kidney damage
|
SG10201908848RA
(en)
|
2010-03-29 |
2019-10-30 |
Univ Pennsylvania |
Pharmacologically induced transgene ablation system
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
WO2011133901A2
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
CA3050894C
(en)
|
2010-04-23 |
2022-10-18 |
University Of Massachusetts |
Multicistronic expression constructs
|
CA2833908C
(en)
|
2010-04-23 |
2021-02-09 |
University Of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
CN107828820B
(en)
|
2010-10-27 |
2022-06-07 |
学校法人自治医科大学 |
Adeno-associated virus particles for gene transfer into nervous system cells
|
DK2673289T3
(en)
*
|
2011-02-10 |
2023-07-24 |
Univ North Carolina Chapel Hill |
VIRUS VECTORS WITH MODIFIED TRANSDUCTION PROFILES AND METHODS FOR THEIR PRODUCTION AND USE
|
BR112013020734A2
(en)
|
2011-02-17 |
2017-06-13 |
Univ Pennsylvania |
compositions and methods for altering tissue specificity and enhancing aav9-mediated gene transfer
|
WO2012145572A1
(en)
|
2011-04-20 |
2012-10-26 |
The Trustees Of The University Of Pennsylvania |
Regimens and compositions for aav-mediated passive immunization of airborne pathogens
|
US9226976B2
(en)
|
2011-04-21 |
2016-01-05 |
University Of Massachusetts |
RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
LT3693025T
(en)
|
2011-04-22 |
2022-02-10 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
US20130039888A1
(en)
*
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
EP3147295B2
(en)
*
|
2011-08-24 |
2023-11-22 |
The Board of Trustees of the Leland Stanford Junior University |
New avv capsid proteins for nucleic acid transfer
|
US8859256B2
(en)
|
2011-10-05 |
2014-10-14 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
US9226936B2
(en)
|
2011-10-28 |
2016-01-05 |
The Wistar of Anatomy and Biology |
Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
|
WO2013082268A1
(en)
|
2011-11-30 |
2013-06-06 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for regulation of cell aging, carcinogenesis, and reprogramming
|
EP2601968A1
(en)
*
|
2011-12-06 |
2013-06-12 |
Deutsches Krebsforschungszentrum |
HPV derived polynucleic acids for therapy
|
WO2013103896A1
(en)
*
|
2012-01-06 |
2013-07-11 |
Mayo Foundation For Medical Education And Research |
Treating cardiovascular or renal diseases
|
US20140087362A1
(en)
|
2012-03-16 |
2014-03-27 |
Aladar A. Szalay |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
WO2013158265A1
(en)
|
2012-04-20 |
2013-10-24 |
Genelux Corporation |
Imaging methods for oncolytic virus therapy
|
EP3470523A1
(en)
*
|
2012-05-09 |
2019-04-17 |
Oregon Health & Science University |
Adeno associated virus plasmids and vectors
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
NZ704275A
(en)
|
2012-07-11 |
2016-09-30 |
Univ Florida |
Aav-mediated gene therapy for rpgr x-linked retinal degeneration
|
CA2880653C
(en)
|
2012-08-01 |
2022-05-17 |
Nationwide Children's Hospital |
Intrathecal delivery of recombinant adeno-associated virus 9
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
EP3738974A1
(en)
|
2012-09-28 |
2020-11-18 |
The University of North Carolina at Chapel Hill |
Aav vectors targeted to oligodendrocytes
|
US20140140959A1
(en)
|
2012-10-05 |
2014-05-22 |
Aladar A. Szalay |
Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
|
EP2749569A1
(en)
|
2012-12-28 |
2014-07-02 |
Annibale Alessandro Puca |
Variant of BPIFB4 protein
|
US8957044B2
(en)
|
2013-03-01 |
2015-02-17 |
Wake Forest University Health Sciences |
Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
|
WO2014160092A1
(en)
*
|
2013-03-13 |
2014-10-02 |
The Children's Hospital Of Philadelphia |
Adeno-associated virus vectors and methods of use thereof
|
JP6628285B2
(en)
|
2013-03-14 |
2020-01-08 |
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド |
ALS-related diamino acid repeat-containing protein
|
EP2984166B1
(en)
|
2013-03-15 |
2020-04-22 |
The Trustees Of The University Of Pennsylvania |
Compositions for treating mpsi
|
JP6396988B2
(en)
*
|
2013-03-15 |
2018-09-26 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
Methods and compositions for double glycan binding AAV vectors
|
US9719106B2
(en)
|
2013-04-29 |
2017-08-01 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
|
JP6600624B2
(en)
|
2013-05-31 |
2019-10-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Adeno-associated virus mutant and method of use thereof
|
EP3561062A1
(en)
|
2013-09-13 |
2019-10-30 |
California Institute of Technology |
Selective recovery
|
US20160369298A1
(en)
|
2013-09-26 |
2016-12-22 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial aav capsid library for targeted gene therapy
|
EP3054995A1
(en)
*
|
2013-10-07 |
2016-08-17 |
Kiromic, LLC |
Compositions and methods for treating cardiovascular diseases using disease-specific promoter
|
CN116574158A
(en)
*
|
2013-10-11 |
2023-08-11 |
马萨诸塞眼科耳科诊所 |
Method for predicting ancestral virus sequence and use thereof
|
WO2015103438A2
(en)
|
2014-01-02 |
2015-07-09 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
GB201403684D0
(en)
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
DK3116900T3
(en)
|
2014-03-09 |
2020-09-28 |
Univ Pennsylvania |
COMPOSITIONS THAT CAN BE USED TO TREAT ORNITHIN TRANSCARBAMYLASE (OTC) DEFECT
|
MX2016011585A
(en)
|
2014-03-10 |
2016-11-29 |
Uniqure Ip Bv |
Further improved aav vectors produced in insect cells.
|
EP3800191A1
(en)
|
2014-03-17 |
2021-04-07 |
Adverum Biotechnologies, Inc. |
Compositions and methods for enhanced gene expression in cone cells
|
DK3119797T3
(en)
|
2014-03-18 |
2021-03-15 |
Univ Massachusetts |
RAAV-BASED COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
|
EP2933335A1
(en)
|
2014-04-18 |
2015-10-21 |
Genethon |
A method of treating peripheral neuropathies and motor neuron diseases
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
US10780182B2
(en)
|
2014-04-25 |
2020-09-22 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
ES2876409T3
(en)
|
2014-04-25 |
2021-11-12 |
Univ Pennsylvania |
Variants of RLBD and their use in compositions to reduce cholesterol levels
|
CA2947614C
(en)
|
2014-05-13 |
2023-10-03 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising aav expressing dual antibody constructs and uses thereof
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
EP2960336A1
(en)
|
2014-06-27 |
2015-12-30 |
Genethon |
Efficient systemic treatment of dystrophic muscle pathologies
|
EP3800260A1
(en)
|
2014-09-24 |
2021-04-07 |
City of Hope |
Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
US10711270B2
(en)
|
2014-10-03 |
2020-07-14 |
University Of Massachusetts |
High efficiency library-identified AAV vectors
|
KR102122463B1
(en)
|
2014-10-14 |
2020-06-15 |
할로자임, 아이엔씨 |
Compositions of Adenosine Deaminase-2 (ADA2), Variants thereof and Methods of Using Same
|
RU2738421C2
(en)
|
2014-10-21 |
2020-12-14 |
Юниверсити Оф Массачусетс |
Versions of recombinant aav and use thereof
|
WO2016073693A2
(en)
*
|
2014-11-05 |
2016-05-12 |
Voyager Therapeutics, Inc. |
Aadc polynucleotides for the treatment of parkinson's disease
|
CA2966884A1
(en)
*
|
2014-11-05 |
2016-05-12 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for producing recombinant viruses in eukaryotic microalgae
|
AU2015346162B2
(en)
|
2014-11-14 |
2022-02-10 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
JP6863891B2
(en)
|
2014-11-14 |
2021-04-21 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
Regulatory polynucleotide
|
EP4344741A2
(en)
|
2014-11-21 |
2024-04-03 |
The University of North Carolina at Chapel Hill |
Aav vectors targeted to the central nervous system
|
WO2016094783A1
(en)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
CA2967468A1
(en)
|
2014-12-16 |
2016-06-23 |
Board Of Regents Of The University Of Nebraska |
Gene therapy for juvenile batten disease
|
CA2974235A1
(en)
|
2015-01-07 |
2016-07-14 |
Universitat Autonoma De Barcelona |
Single-vector gene construct comprising insulin and glucokinase genes
|
SG11201705324UA
(en)
|
2015-01-16 |
2017-07-28 |
Univ Washington |
Novel micro-dystrophins and related methods of use
|
WO2016126857A1
(en)
|
2015-02-03 |
2016-08-11 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
EA201791939A1
(en)
|
2015-03-02 |
2018-01-31 |
Адверум Байотекнолоджиз, Инк. |
COMPOSITIONS AND METHODS OF INTRAVITREAL DELIVERY OF POLYNUCLEOTIDES IN RETCHEMBALS
|
MX2017011615A
(en)
|
2015-03-10 |
2018-04-11 |
Univ Columbia |
Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression.
|
AU2016235163B2
(en)
*
|
2015-03-24 |
2022-03-24 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
CA3021949C
(en)
|
2015-04-24 |
2023-10-17 |
University Of Massachusetts |
Modified aav constructs and uses thereof
|
EP3288594B1
(en)
|
2015-04-27 |
2022-06-29 |
The Trustees of The University of Pennsylvania |
Dual aav vector system for crispr/cas9 mediated correction of human disease
|
AU2016256894B2
(en)
|
2015-05-07 |
2020-11-26 |
Massachusetts Eye And Ear Infirmary |
Methods of delivering an agent to the eye
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
WO2016183297A1
(en)
*
|
2015-05-12 |
2016-11-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Aav isolate and fusion protein comprising nerve growth factor signal peptide and parathyroid hormone
|
EP3307310A2
(en)
|
2015-05-13 |
2018-04-18 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated expression of anti-influenza antibodies and methods of use thereof
|
US20170067028A1
(en)
*
|
2015-05-15 |
2017-03-09 |
Douglas J. Ballon |
Radiolabeling of adeno associated virus
|
WO2016196324A1
(en)
|
2015-05-29 |
2016-12-08 |
University Of Floridia Research Foundation, Inc. |
Methods for diagnosing huntington's disease
|
EP3325018A4
(en)
|
2015-07-22 |
2019-04-24 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
PL3872085T3
(en)
*
|
2015-07-30 |
2023-06-05 |
Massachusetts Eye & Ear Infirmary |
Ancestral aav sequences and uses thereof
|
EP3328399B1
(en)
|
2015-07-31 |
2023-12-27 |
Regents of the University of Minnesota |
Modified cells and methods of therapy
|
EP3341727B1
(en)
|
2015-08-25 |
2022-08-10 |
Duke University |
Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
|
CN108137664B
(en)
|
2015-08-31 |
2021-11-26 |
宾夕法尼亚州大学信托人 |
AAV-EPO for treatment of companion animals
|
JP7261583B2
(en)
|
2015-09-24 |
2023-04-20 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Compositions and methods for treating complement-mediated diseases
|
CN114606267A
(en)
|
2015-09-28 |
2022-06-10 |
北卡罗来纳-查佩尔山大学 |
Methods and compositions for antibody-evading viral vectors
|
US11273227B2
(en)
|
2015-10-09 |
2022-03-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating Stargardt's disease and other ocular disorders
|
WO2017066497A2
(en)
|
2015-10-13 |
2017-04-20 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
WO2017066764A2
(en)
|
2015-10-16 |
2017-04-20 |
William Marsh Rice University |
Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
|
EP3364997B1
(en)
|
2015-10-22 |
2024-01-17 |
University of Massachusetts |
Aspartoacylase gene therapy in the treatment of canavan disease
|
WO2017070476A2
(en)
*
|
2015-10-22 |
2017-04-27 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial aav3 capsid library
|
WO2017070516A1
(en)
*
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
WO2017070491A1
(en)
*
|
2015-10-23 |
2017-04-27 |
Applied Genetic Technologies Corporation |
Ophthalmic formulations
|
EP3368563A1
(en)
|
2015-10-28 |
2018-09-05 |
The Trustees Of The University Of Pennsylvania |
Intrathecal administration of adeno-associated-viral vectors for gene therapy
|
WO2017075335A1
(en)
|
2015-10-28 |
2017-05-04 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
KR102200642B1
(en)
|
2015-11-05 |
2021-01-12 |
뱀부 테라퓨틱스 인코포레이티드 |
Modified Friedreich ataxia genes and vectors for gene therapy
|
WO2017096162A1
(en)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
FR3044926B1
(en)
|
2015-12-09 |
2020-01-31 |
Genethon |
EFFICIENT GENE THERAPY TOOLS FOR JUMPING DYSTROPHIN EXON 53
|
CN115957350A
(en)
|
2015-12-11 |
2023-04-14 |
宾夕法尼亚州大学信托人 |
Gene therapy for the treatment of familial hypercholesterolemia
|
CO2018007203A2
(en)
*
|
2015-12-11 |
2018-09-20 |
California Inst Of Techn |
Focalization of peptides to direct adeno-associated viruses (aavs)
|
US11015173B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV1
|
EP3984550A1
(en)
|
2015-12-11 |
2022-04-20 |
Massachusetts Eye & Ear Infirmary |
Materials and methods for delivering nucleic acids to cochlear and vestibular cells
|
US11098286B2
(en)
|
2015-12-11 |
2021-08-24 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV9
|
US11015174B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV8
|
ES2918998T3
(en)
|
2015-12-11 |
2022-07-21 |
Univ Pennsylvania |
Scalable purification method for AAVrh10
|
JP7061067B2
(en)
|
2015-12-14 |
2022-04-27 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Composition for the treatment of Crigler-Najer syndrome
|
WO2017106354A1
(en)
*
|
2015-12-14 |
2017-06-22 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated viral vectors useful in treatment of spinal muscular atropy
|
KR20180099719A
(en)
|
2015-12-14 |
2018-09-05 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Gene therapy for eye disorders
|
CA3011939A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
KR20180121899A
(en)
|
2016-02-03 |
2018-11-09 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Gene therapy to treat type I mucopolysaccharidosis
|
DK3411484T3
(en)
|
2016-02-05 |
2023-11-20 |
Univ Emory |
INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID
|
WO2017139643A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
EP3440100A4
(en)
|
2016-04-04 |
2020-01-22 |
University of Florida Research Foundation, Incorporated |
Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
|
US11207426B2
(en)
|
2016-04-05 |
2021-12-28 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
SG11201808783XA
(en)
|
2016-04-15 |
2018-11-29 |
Alpine Immune Sciences Inc |
Cd80 variant immunomodulatory proteins and uses thereof
|
EP3452104A1
(en)
|
2016-04-15 |
2019-03-13 |
The Trustees of The University of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
NZ746741A
(en)
|
2016-04-15 |
2023-12-22 |
Alpine Immune Sciences Inc |
Icos ligand variant immunomodulatory proteins and uses thereof
|
WO2017181105A1
(en)
|
2016-04-15 |
2017-10-19 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
CA3019425A1
(en)
|
2016-04-15 |
2017-10-19 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating hemophilia a
|
EP3452103A1
(en)
|
2016-04-15 |
2019-03-13 |
The Trustees Of The University Of Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
SG10202009852PA
(en)
*
|
2016-04-15 |
2020-11-27 |
Univ Pennsylvania |
Novel aav8 mutant capsids and compositions containing same
|
WO2017184463A1
(en)
|
2016-04-17 |
2017-10-26 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for prophylaxis of organophosphates
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
EP3452495B1
(en)
*
|
2016-05-03 |
2021-06-23 |
Children's Medical Research Institute |
Adeno-associated virus polynucleotides, polypeptides and virions
|
KR102234930B1
(en)
|
2016-05-13 |
2021-04-02 |
4디 몰레큘러 테라퓨틱스 아이엔씨. |
Adeno-associated virus variant capsid and uses thereof
|
EP3458589A4
(en)
|
2016-05-18 |
2020-01-01 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
IL302748A
(en)
|
2016-05-18 |
2023-07-01 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
EP3469080A4
(en)
|
2016-06-13 |
2020-01-22 |
The University of North Carolina at Chapel Hill |
Optimized cln1 genes and expression cassettes and their use
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
CA2971303A1
(en)
|
2016-06-21 |
2017-12-21 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
IL264070B2
(en)
|
2016-07-08 |
2023-03-01 |
Univ Pennsylvania |
Methods and compositions for treatment of disorders and diseases involving rdh12
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
US11584780B2
(en)
*
|
2016-07-26 |
2023-02-21 |
Biomarin Pharmaceutical Inc. |
Adeno-associated virus capsid proteins
|
CA3032120A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
KR20230039779A
(en)
|
2016-07-29 |
2023-03-21 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
CN110650673B
(en)
|
2016-08-30 |
2024-04-09 |
加利福尼亚大学董事会 |
Methods for biomedical targeting and delivery and devices and systems for practicing the methods
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
WO2018075664A1
(en)
|
2016-10-18 |
2018-04-26 |
Regents Of The University Of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
US11192925B2
(en)
|
2016-10-19 |
2021-12-07 |
Adverum Biotechnologies, Inc. |
Modified AAV capsids and uses thereof
|
CN110352245A
(en)
|
2016-10-20 |
2019-10-18 |
高山免疫科学股份有限公司 |
Variant immune modulator and engineering cell therapy can be secreted
|
US20180245065A1
(en)
|
2016-11-01 |
2018-08-30 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
US20190328846A1
(en)
|
2016-12-01 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for the treatment of retinal degenerative diseases
|
EP3562514A4
(en)
|
2016-12-30 |
2020-08-05 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating wilson's disease
|
CA3048038A1
(en)
|
2016-12-30 |
2018-07-05 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating phenylketonuria
|
WO2018134168A1
(en)
|
2017-01-17 |
2018-07-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of expressing a polynucleotide of interest in the cone photoreceptors
|
EP3576760A2
(en)
|
2017-02-01 |
2019-12-11 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating citrullenemia
|
CN110546265A
(en)
|
2017-02-09 |
2019-12-06 |
因达普塔治疗公司 |
Engineered Natural Killer (NK) cells and compositions and methods thereof
|
US11554147B2
(en)
|
2017-02-20 |
2023-01-17 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
JP7237843B2
(en)
|
2017-02-21 |
2023-03-13 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. |
Modified AAV capsid proteins and uses thereof
|
EP3655533A1
(en)
|
2017-02-24 |
2020-05-27 |
Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin |
Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated rasal,1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including rasal1 in a subject
|
JOP20190200A1
(en)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
Compositions useful in treatment of spinal muscular atrophy
|
SG10201913833PA
(en)
*
|
2017-02-28 |
2020-03-30 |
Univ Pennsylvania |
Influenza vaccines based on aav vectors
|
WO2018160582A1
(en)
*
|
2017-02-28 |
2018-09-07 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (aav) clade f vector and uses therefor
|
CN110582572A
(en)
|
2017-03-01 |
2019-12-17 |
宾夕法尼亚州立大学托管会 |
Gene therapy for ocular disorders
|
US11376321B2
(en)
|
2017-03-02 |
2022-07-05 |
Genethon |
Method for removing anti-AAV antibodies from a blood-derived composition
|
CA3053812A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Pd-l2 variant immunomodulatory proteins and uses thereof
|
BR112019018747A2
(en)
|
2017-03-16 |
2020-05-05 |
Alpine Immune Sciences Inc |
variant immunomodulatory proteins of cd80 and uses thereof
|
JP2020509776A
(en)
|
2017-03-16 |
2020-04-02 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
PD-L1 variant immunomodulatory proteins and uses thereof
|
SG10202110530WA
(en)
|
2017-03-24 |
2021-11-29 |
Lankenau Inst Medical Res |
Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
|
US20210108197A1
(en)
|
2017-03-31 |
2021-04-15 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Shrna expression cassette, polynucleotide sequence carrying same, and application thereof
|
EP3610016A1
(en)
|
2017-04-10 |
2020-02-19 |
Genethon |
Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
|
BR112019021569A2
(en)
|
2017-04-14 |
2020-05-12 |
Regenxbio Inc. |
PRECURSOR OF GLUCOSYLATED RECOMBINANT HUMAN IDURONATE-2-SULPHATASE (IDS), METHOD FOR TREATING A HUMAN SUBJECT DIAGNOSED WITH TYPE II MUCOPOLYSACARIDOSIS (MPS II)
|
EP3612190A4
(en)
*
|
2017-04-17 |
2021-01-20 |
University of Florida Research Foundation, Incorporated |
Regulation of ran translation by pkr and eif2a-p pathways
|
EP3634986A4
(en)
|
2017-04-24 |
2021-09-08 |
The Trustees of The University of Pennsylvania |
Gene therapy for ocular disorders
|
WO2018204786A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
MX2019013172A
(en)
|
2017-05-05 |
2020-09-07 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease.
|
CA3059213A1
(en)
|
2017-05-09 |
2018-11-15 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (als)
|
AU2018265414B2
(en)
|
2017-05-10 |
2022-01-20 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (APP)-dependence of viruses
|
SG11201910015SA
(en)
|
2017-05-11 |
2019-11-28 |
Univ Pennsylvania |
Gene therapy for neuronal ceroid lipofuscinoses
|
EP3630986A4
(en)
|
2017-05-31 |
2021-08-11 |
The Trustees of The University of Pennsylvania |
Gene therapy for treating peroxisomal disorders
|
US11827898B2
(en)
|
2017-06-14 |
2023-11-28 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
JOP20190269A1
(en)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
Aadc polynucleotides for the treatment of parkinson's disease
|
WO2019006418A2
(en)
*
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
Adeno-associated viral vectors for gene therapy
|
JP2020526514A
(en)
|
2017-07-06 |
2020-08-31 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Gene therapy to treat mucopolysaccharidosis type I
|
EP3648783A1
(en)
|
2017-07-07 |
2020-05-13 |
Genethon |
Novel polynucleotides encoding a human fkrp protein
|
WO2019018342A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
KR20200032722A
(en)
|
2017-07-27 |
2020-03-26 |
노파르티스 아게 |
Partial cleavage resistance TREM2 variant
|
JP7221275B2
(en)
|
2017-08-03 |
2023-02-13 |
ボイジャー セラピューティクス インコーポレイテッド |
Compositions and methods for delivering AAV
|
US11680249B2
(en)
|
2017-08-28 |
2023-06-20 |
The Regents Of The University Of California |
Adeno-associated virus capsid variants and methods of use thereof
|
EP4218828A3
(en)
|
2017-09-20 |
2023-09-27 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and methods of use thereof
|
AU2018338188A1
(en)
|
2017-09-22 |
2020-04-02 |
University Of Massachusetts |
SOD1 dual expression vectors and uses thereof
|
US11819539B2
(en)
|
2017-09-22 |
2023-11-21 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating Mucopolysaccharidosis type II
|
AU2018342105B2
(en)
|
2017-09-26 |
2023-11-16 |
University Of Florida Research Foundation, Incorporated |
Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
|
CA3077426A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
TW201925223A
(en)
|
2017-10-18 |
2019-07-01 |
美商艾爾潘免疫科學有限公司 |
Variant ICOS ligand immunomodulatory proteins and related compositions and methods
|
WO2019079496A2
(en)
|
2017-10-18 |
2019-04-25 |
Regenxbio, Inc. |
Fully-human post-translationally modified antibody therapeutics
|
MX2020003945A
(en)
|
2017-10-18 |
2020-11-09 |
Regenxbio Inc |
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap.
|
CN111867635A
(en)
|
2017-10-20 |
2020-10-30 |
法国国家卫生及研究医学协会 |
Methods of expressing a polynucleotide of interest in cone photoreceptors of a subject comprising subretinal delivery of a therapeutically effective amount of a recombinant AAV 9-derived vector
|
JP7184894B2
(en)
|
2017-11-27 |
2022-12-06 |
4ディー モレキュラー セラピューティクス インコーポレイテッド |
Adeno-associated virus mutated capsid and use for inhibition of angiogenesis
|
US11723989B2
(en)
|
2017-11-30 |
2023-08-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for mucopolysaccharidosis IIIB
|
US11555206B2
(en)
|
2017-11-30 |
2023-01-17 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for mucopolysaccharidosis IIIA
|
EP3727468A4
(en)
|
2017-12-19 |
2021-09-22 |
Akouos, Inc. |
Aav-mediated delivery of therapeutic antibodies to the inner ear
|
US20210277365A1
(en)
|
2018-01-17 |
2021-09-09 |
Adrenas Therapeutics, Inc. |
Adeno-associated virus gene therapy for 21-hydroxylase deficiency
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
EP3755795A4
(en)
|
2018-02-19 |
2022-07-20 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof
|
CA3091795A1
(en)
*
|
2018-02-27 |
2019-09-06 |
The Trustees Of The University Of Pennsylvania |
Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
|
WO2019168961A1
(en)
*
|
2018-02-27 |
2019-09-06 |
The Trustees Of The University Of Pennsylvania |
Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
|
JP7304878B2
(en)
*
|
2018-03-16 |
2023-07-07 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
Increased tissue-specific gene delivery by capsid modification
|
US20210107948A1
(en)
|
2018-04-05 |
2021-04-15 |
Genethon |
Hybrid Recombinant Adeno-Associated Virus Serotype Between AAV9 and AAVrh74 with Reduced Liver Tropism
|
EP3787771A1
(en)
|
2018-04-29 |
2021-03-10 |
REGENXBIO Inc. |
Scalable clarification process for recombinant aav production
|
US20210231560A1
(en)
|
2018-04-29 |
2021-07-29 |
Regenxbio Inc. |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
SG11202009914SA
(en)
|
2018-05-08 |
2020-11-27 |
Rutgers The State University Of New Jersey |
Aav-compatible laminin-linker polymerization proteins
|
BR112020022722A8
(en)
|
2018-05-09 |
2022-01-18 |
Biomarin Pharm Inc |
Genome and its use, vector, particle, isolated nucleic acid molecule, nucleic acid, composition, treatment, method
|
TW202005978A
(en)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
Novel liver targeting adeno-associated viral vectors
|
EP3793616A1
(en)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
BR112020023082A2
(en)
|
2018-05-15 |
2021-02-09 |
Voyager Therapeutics, Inc. |
compositions and methods for the treatment of parkinson's disease
|
AR126019A1
(en)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
|
US11505782B2
(en)
|
2018-06-04 |
2022-11-22 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
KR20210022010A
(en)
|
2018-06-04 |
2021-03-02 |
카리디 바이오테라퓨틱스, 인크. |
Cell-based vehicles for enhancing viral therapy
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
US20210301305A1
(en)
|
2018-06-13 |
2021-09-30 |
Voyager Therapeutics, Inc. |
Engineered untranslated regions (utr) for aav production
|
AU2019285186A1
(en)
|
2018-06-14 |
2021-01-07 |
Regenxbio Inc. |
Anion exchange chromatography for recombinant AAV production
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
US20210322473A1
(en)
*
|
2018-07-18 |
2021-10-21 |
The General Hospital Corporation |
Modified t cells and methods of their use
|
JP2021530548A
(en)
|
2018-07-24 |
2021-11-11 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. |
Systems and methods for producing gene therapy products
|
US20210277418A1
(en)
|
2018-08-03 |
2021-09-09 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
KR20210043580A
(en)
|
2018-08-10 |
2021-04-21 |
리젠엑스바이오 인크. |
A scalable method for production of recombinant AAV
|
WO2020047161A2
(en)
|
2018-08-28 |
2020-03-05 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
CA3111076A1
(en)
|
2018-08-30 |
2020-03-05 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with myocardin and ascl1
|
EP3856913A4
(en)
|
2018-09-26 |
2022-10-26 |
California Institute Of Technology |
Adeno-associated virus compositions for targeted gene therapy
|
AU2019346655A1
(en)
|
2018-09-28 |
2021-05-06 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
KR20210068104A
(en)
|
2018-10-01 |
2021-06-08 |
토루 미야자키 |
Neurodegenerative disease treatment
|
SG11202102942VA
(en)
|
2018-10-01 |
2021-04-29 |
Univ Pennsylvania |
Compositions useful for treating gm1 gangliosidosis
|
TW202035689A
(en)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
Methods for measuring the titer and potency of viral vector particles
|
EP3861107A1
(en)
|
2018-10-05 |
2021-08-11 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
UY38407A
(en)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
TREM2 STABILIZING ANTIBODIES
|
CA3115524A1
(en)
|
2018-10-15 |
2020-04-23 |
Win Den Cheung |
Methods for measuring the infectivity of replication defective viral vectors and viruses
|
CA3116701A1
(en)
|
2018-10-15 |
2020-04-23 |
Voyager Therapeutics, Inc. |
Expression vectors for large-scale production of raav in the baculovirus/sf9 system
|
JP2022513376A
(en)
|
2018-10-22 |
2022-02-07 |
ユニバーシティ オブ ロチェスター |
Genome editing by directional non-homologous DNA insertion using retrovirus integrase-Cas9 fusion protein
|
WO2020086742A1
(en)
|
2018-10-24 |
2020-04-30 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
JP7329593B2
(en)
|
2018-11-06 |
2023-08-18 |
カリディ・バイオセラピューティクス・インコーポレイテッド |
An enhanced system for cell-mediated oncolytic virus therapy
|
SG11202105030VA
(en)
|
2018-11-16 |
2021-06-29 |
Astellas Pharma Inc |
Method for treating muscular dystrophy by targeting utrophin gene
|
EP3884041A2
(en)
|
2018-11-21 |
2021-09-29 |
Indapta Therapeutics, Inc. |
Methods for expansion of natural killer (nk) cell subset and related compositions and methods
|
AU2019389151A1
(en)
|
2018-11-30 |
2021-06-10 |
Alpine Immune Sciences, Inc. |
CD86 variant immunomodulatory proteins and uses thereof
|
WO2020140007A1
(en)
|
2018-12-28 |
2020-07-02 |
University Of Rochester |
Gene therapy for best1 dominant mutations
|
US20220090131A1
(en)
|
2019-01-04 |
2022-03-24 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy constructs for treating wilson disease
|
MX2021008487A
(en)
|
2019-01-14 |
2021-11-12 |
Univ Rochester |
Targeted nuclear rna cleavage and polyadenylation with crispr-cas.
|
EP3911410A1
(en)
|
2019-01-18 |
2021-11-24 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
CA3128230A1
(en)
|
2019-01-31 |
2020-08-06 |
Oregon Health & Science University |
Methods for using transcription-dependent directed evolution of aav capsids
|
SG11202108504YA
(en)
|
2019-02-22 |
2021-09-29 |
Univ Pennsylvania |
Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
|
SG11202108044YA
(en)
|
2019-02-25 |
2021-09-29 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
JP2022520875A
(en)
|
2019-02-25 |
2022-04-01 |
ノバルティス アーゲー |
Compositions and Methods for Treating Bietti Crystallin Retinopathy
|
CN114040980A
(en)
|
2019-02-26 |
2022-02-11 |
宾夕法尼亚州大学信托人 |
Compositions useful for treating krabbe's disease
|
CA3176660A1
(en)
|
2019-02-27 |
2020-09-03 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
EP3947427A1
(en)
|
2019-03-25 |
2022-02-09 |
Genethon |
Production of large-sized quasidystrophins using overlapping aav vectors
|
EP3946467A1
(en)
|
2019-04-03 |
2022-02-09 |
REGENXBIO Inc. |
Gene therapy for eye pathologies
|
TW202102526A
(en)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
Recombinant adeno-associated viruses and uses thereof
|
FI3953483T3
(en)
|
2019-04-11 |
2023-11-30 |
Regenxbio Inc |
Methods of size exclusion chromatography for the characterization of recombinant adeno-associated virus compositions
|
JP2022529002A
(en)
|
2019-04-19 |
2022-06-16 |
レジェンクスバイオ インコーポレーテッド |
Adeno-associated virus vector preparation and method
|
EP3959323A1
(en)
|
2019-04-24 |
2022-03-02 |
REGENXBIO Inc. |
Fully-human post-translationally modified antibody therapeutics
|
US20220220453A1
(en)
*
|
2019-04-29 |
2022-07-14 |
The Trustees Of The University Of Pennsylvania |
Novel aav capsids and compositions containing same
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
EP3962536A1
(en)
|
2019-04-29 |
2022-03-09 |
Voyager Therapeutics, Inc. |
Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
WO2020232044A1
(en)
|
2019-05-14 |
2020-11-19 |
Biomarin Pharmaceutical Inc. |
Methods of redosing gene therapy vectors
|
EP3976785A1
(en)
|
2019-05-28 |
2022-04-06 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting dmpk gene
|
CN114207120A
(en)
|
2019-05-30 |
2022-03-18 |
坚固生物科技公司 |
Recombinant herpesvirus vectors
|
US20230241248A1
(en)
|
2019-06-27 |
2023-08-03 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
TW202122579A
(en)
|
2019-07-02 |
2021-06-16 |
美商M6P生物醫藥公司 |
Vector compositions and methods of using same for treatment of lysosomal storage disorders
|
WO2021005223A1
(en)
|
2019-07-10 |
2021-01-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
WO2021007515A1
(en)
|
2019-07-11 |
2021-01-14 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
WO2021005210A1
(en)
|
2019-07-11 |
2021-01-14 |
Centre National De La Recherche Scientifique |
Chemically-modified adeno-associated virus
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
WO2021016453A1
(en)
|
2019-07-23 |
2021-01-28 |
University Of Rochester |
Targeted rna cleavage with crispr-cas
|
WO2021021674A1
(en)
|
2019-07-26 |
2021-02-04 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
WO2021021661A1
(en)
|
2019-07-26 |
2021-02-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
WO2021030125A1
(en)
|
2019-08-09 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
CA3146751A1
(en)
|
2019-08-16 |
2021-02-25 |
Yuanbo QIN |
Method for treating muscular dystrophy by targeting lama1 gene
|
US20220288235A1
(en)
*
|
2019-08-20 |
2022-09-15 |
St. Jude Children's Research Hospital, Inc. |
SCHIZOPHRENIA-RELATED MICRODELETION GENE 2510002D24Rik IS ESSENTIAL FOR SOCIAL MEMORY
|
WO2021041373A1
(en)
|
2019-08-26 |
2021-03-04 |
Regenxbio Inc. |
Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab
|
WO2021040736A1
(en)
|
2019-08-30 |
2021-03-04 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
CN114555814A
(en)
|
2019-09-13 |
2022-05-27 |
罗特格斯新泽西州立大学 |
AAV-compatible laminin-linker polyproteins
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
TW202124446A
(en)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
Combination therapies with entpd2 antibodies
|
EP4031673A1
(en)
|
2019-09-19 |
2022-07-27 |
Genethon |
Gene therapy expression system alleviating cardiac toxicity of fkrp
|
JP2022550435A
(en)
|
2019-10-04 |
2022-12-01 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
Methods for improved therapeutic use of recombinant AAV
|
MX2022004146A
(en)
|
2019-10-07 |
2022-09-19 |
Regenxbio Inc |
Adeno-associated virus vector pharmaceutical composition and methods.
|
CN115003820A
(en)
|
2019-10-08 |
2022-09-02 |
爱科霍拉有限公司 |
Compositions and methods for ocular treatment
|
US11905523B2
(en)
|
2019-10-17 |
2024-02-20 |
Ginkgo Bioworks, Inc. |
Adeno-associated viral vectors for treatment of Niemann-Pick Disease type-C
|
WO2021092300A1
(en)
*
|
2019-11-08 |
2021-05-14 |
President And Fellows Of Harvard College |
Viral capsid polypeptides
|
EP4061943A1
(en)
|
2019-11-19 |
2022-09-28 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antisense oligonucleotides and their use for the treatment of cancer
|
AU2020392243A1
(en)
|
2019-11-28 |
2022-06-16 |
Regenxbio Inc. |
Microdystrophin gene therapy constructs and uses thereof
|
EP4073257A1
(en)
|
2019-12-09 |
2022-10-19 |
UCL Business Ltd |
Gene therapy composition and treatment for myh7-linked cardiomyopathy
|
MX2022007135A
(en)
|
2019-12-10 |
2022-09-19 |
Takeda Pharmaceuticals Co |
Adeno associated virus vectors for the treatment of hunter disease.
|
TW202140791A
(en)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
Methods of treating phenylketonuria
|
EP4093428A1
(en)
|
2020-01-22 |
2022-11-30 |
RegenxBio Inc. |
Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)
|
KR20220148162A
(en)
|
2020-01-29 |
2022-11-04 |
리젠엑스바이오 인크. |
Treatment of Mucopolysaccharidosis II with Recombinant Human Iduronate-2-sulfatase (IDS) Produced by Human Neuronal or Glia Cells
|
CA3168251A1
(en)
|
2020-01-29 |
2021-08-05 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis iva
|
KR20220145838A
(en)
|
2020-02-02 |
2022-10-31 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Compositions useful for treating GM1 gangliosiosis
|
JP2023513211A
(en)
|
2020-02-07 |
2023-03-30 |
ユニバーシティ オブ ロチェスター |
Target RNA translation by CRISPR-Cas13 to enhance protein synthesis
|
CN115335526A
(en)
|
2020-02-07 |
2022-11-11 |
罗切斯特大学 |
Ribozyme-mediated RNA assembly and expression
|
JP2023514204A
(en)
|
2020-02-14 |
2023-04-05 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
Gene therapy to treat CDKL5 deficiency disorders
|
EP4110373A1
(en)
|
2020-02-28 |
2023-01-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gene therapy for maple syrup urine disease
|
EP4114421A1
(en)
|
2020-03-02 |
2023-01-11 |
Tenaya Therapeutics, Inc. |
Gene vector control by cardiomyocyte-expressed micrornas
|
KR20220150353A
(en)
|
2020-03-05 |
2022-11-10 |
네오티엑스 테라퓨틱스 엘티디. |
Methods and compositions for treating cancer using immune cells
|
KR20220153604A
(en)
|
2020-03-11 |
2022-11-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Methods and Compositions for Gene Delivery Using Engineered Viral Particles
|
JP2023518415A
(en)
|
2020-03-19 |
2023-05-01 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
Compositions and methods for reducing reverse packaging of CAP and REP sequences in recombinant AAV
|
US20230103771A1
(en)
|
2020-03-27 |
2023-04-06 |
University Of Rochester |
CRISPR-Cas13 crRNA Arrays
|
US20240024520A1
(en)
|
2020-03-27 |
2024-01-25 |
UCB Biopharma SRL |
Autonomous knob domain peptides
|
EP4127169A1
(en)
|
2020-03-27 |
2023-02-08 |
University of Rochester |
Targeted destruction of viral rna by crispr-cas13
|
JP2023520402A
(en)
|
2020-03-31 |
2023-05-17 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
Gene therapy to treat propionic acidemia
|
US20230131352A1
(en)
|
2020-04-01 |
2023-04-27 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
EP4132955A2
(en)
|
2020-04-10 |
2023-02-15 |
SOLA Biosciences LLC |
Compositions and methods for the treatment of protein aggregation disorders
|
AU2021257848A1
(en)
|
2020-04-15 |
2022-12-01 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2021216790A1
(en)
|
2020-04-22 |
2021-10-28 |
Indapta Therapeutics, Inc. |
Natural killer (nk) cell compositions and methods for generating same
|
BR112022021604A2
(en)
|
2020-04-28 |
2022-12-06 |
Sola Biosciences Llc |
COMPOSITIONS AND METHODS FOR TREATMENT OF PROTEINOPATHIES ASSOCIATED WITH TDP-43
|
CN116096377A
(en)
*
|
2020-05-05 |
2023-05-09 |
杜克大学 |
Cross-species compatible adeno-associated virus compositions and methods of use thereof
|
EP4162059A1
(en)
|
2020-05-12 |
2023-04-12 |
The Trustees of The University of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
MX2022014245A
(en)
|
2020-05-12 |
2023-02-22 |
Univ Pennsylvania |
Compositions useful in treatment of krabbe disease.
|
EP4165195A2
(en)
|
2020-05-13 |
2023-04-19 |
Akouos, Inc. |
Compositions and methods for treating slc26a4-associated hearing loss
|
EP4149955A1
(en)
|
2020-05-13 |
2023-03-22 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
US20230212606A1
(en)
|
2020-05-13 |
2023-07-06 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
WO2021236908A2
(en)
|
2020-05-20 |
2021-11-25 |
Biomarin Pharmaceutical Inc. |
Use of regulatory proteins for the production of adeno-associated virus
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
CN116096737A
(en)
|
2020-06-05 |
2023-05-09 |
索拉生物科学有限公司 |
Compositions and methods for treating synucleinopathies
|
KR20230025000A
(en)
|
2020-06-17 |
2023-02-21 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Compositions and methods for the treatment of gene therapy patients
|
CN115996758A
(en)
|
2020-06-19 |
2023-04-21 |
吉尼松公司 |
Gene therapy expression system for enabling SGCG to be fully expressed in muscle and heart
|
IL299638A
(en)
*
|
2020-07-07 |
2023-03-01 |
Univ Texas |
Adeno-associated virus vector for dwarf open reading frame
|
WO2022008711A1
(en)
|
2020-07-10 |
2022-01-13 |
Genethon |
A novel muscle-specific promoter
|
WO2022011262A1
(en)
|
2020-07-10 |
2022-01-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating epilepsy
|
CA3185281A1
(en)
|
2020-07-13 |
2022-01-20 |
James M. Wilson |
Compositions useful for treatment of charcot-marie-tooth disease
|
EP4182455A1
(en)
|
2020-07-15 |
2023-05-24 |
University of Rochester |
Targeted rna cleavage with dcasl3-rnase fusion proteins
|
JP2023536091A
(en)
|
2020-07-27 |
2023-08-23 |
ボイジャー セラピューティクス インコーポレイテッド |
Compositions and methods for the treatment of neurological disorders associated with glucosylceramidase beta deficiency
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
EP4192514A1
(en)
|
2020-08-06 |
2023-06-14 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
AU2021328570A1
(en)
|
2020-08-17 |
2023-03-09 |
Massachusetts Institute Of Technology |
Shank3 gene therapy approaches
|
MX2023002293A
(en)
|
2020-08-24 |
2023-05-19 |
Univ Pennsylvania |
Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases.
|
EP4204014A1
(en)
|
2020-08-26 |
2023-07-05 |
The Trustees of The University of Pennsylvania |
Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
|
EP4209589A1
(en)
|
2020-09-04 |
2023-07-12 |
National University Corporation Kobe University |
Miniaturized cytidine deaminase-containing complex for modifying double-stranded dna
|
EP4213890A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized lanadelumab and administration thereof
|
WO2022060916A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized antibodies for anti-viral therapy
|
US20230383278A1
(en)
|
2020-09-18 |
2023-11-30 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
JP2023544803A
(en)
|
2020-10-07 |
2023-10-25 |
レジェンクスバイオ インコーポレーテッド |
Gene therapy for ocular symptoms of CLN2 disease
|
US20230372538A1
(en)
|
2020-10-07 |
2023-11-23 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
WO2022076595A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as gel formulations
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
KR20230082614A
(en)
|
2020-10-07 |
2023-06-08 |
리젠엑스바이오 인크. |
Adeno-associated virus for ocular delivery of gene therapy
|
TW202228648A
(en)
|
2020-10-07 |
2022-08-01 |
美商銳進科斯生物股份有限公司 |
Formulations for suprachoroidal administration such as high viscosity formulations
|
CA3193833A1
(en)
|
2020-10-09 |
2022-04-14 |
Juliette HORDEAUX |
Compositions and methods for treatment of fabry disease
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
CA3195553A1
(en)
|
2020-10-18 |
2022-04-21 |
Qiang Wang |
Improved adeno-associated virus (aav) vector and uses therefor
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
US20230391864A1
(en)
|
2020-10-28 |
2023-12-07 |
Regenxbio, Inc. |
Vectorized anti-tnf-alpha antibodies for ocular indications
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
US20230390418A1
(en)
|
2020-10-29 |
2023-12-07 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
EP4237453A1
(en)
|
2020-10-29 |
2023-09-06 |
RegenxBio Inc. |
Vectorized tnf-alpha antagonists for ocular indications
|
KR20230078805A
(en)
|
2020-11-02 |
2023-06-02 |
바이오마린 파머수티컬 인크. |
Enrichment process of adeno-associated virus
|
JP2023548816A
(en)
|
2020-11-03 |
2023-11-21 |
ファイザー・インク |
Method for purifying AAV vectors by anion exchange chromatography
|
CN116670152A
(en)
|
2020-12-01 |
2023-08-29 |
宾夕法尼亚州大学信托人 |
Novel compositions having tissue-specific targeting motifs and compositions containing the same
|
JP2023551911A
(en)
|
2020-12-01 |
2023-12-13 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Compositions and uses thereof for the treatment of Angelman syndrome
|
KR20230117179A
(en)
|
2020-12-01 |
2023-08-07 |
아카우오스, 인크. |
Anti-VEGF antibody constructs and related methods for treating symptoms associated with acoustic schwannoma
|
US20240052322A1
(en)
|
2020-12-15 |
2024-02-15 |
Pfizer Inc. |
HILIC UPLC-MS Method For Separating and Analyzing Intact Adeno-Associated Virus Capsid Proteins
|
JP2023554389A
(en)
|
2020-12-16 |
2023-12-27 |
リジェネクスバイオ インコーポレイテッド |
Method for producing recombinant adeno-associated virus virus particles
|
IL303959A
(en)
|
2020-12-23 |
2023-08-01 |
Pfizer |
Methods for purification of aav vectors by affinity chromatography
|
WO2022147087A1
(en)
|
2020-12-29 |
2022-07-07 |
Regenxbio Inc. |
Tau-specific antibody gene therapy compositions, methods and uses thereof
|
AU2021412962A1
(en)
|
2020-12-29 |
2023-08-17 |
Akouos, Inc. |
Compositions and methods for treating clrn1-associated hearing loss and/or vision loss
|
TW202241479A
(en)
|
2020-12-30 |
2022-11-01 |
美商安迅生物製藥公司 |
Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
|
WO2022159662A1
(en)
|
2021-01-21 |
2022-07-28 |
Regenxbio Inc. |
Improved production of recombinant polypeptides and viruses
|
KR20230149299A
(en)
*
|
2021-01-25 |
2023-10-26 |
트라메스 바이오 인코포레이티드 |
Adeno-Associated Viral Capsids and Engineered Ligand-gated Ion Channels for the Treatment of Focal Epilepsy and Neuropathic Pain
|
AU2022214429A1
(en)
|
2021-02-01 |
2023-09-14 |
Regenxbio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
US11926842B2
(en)
*
|
2021-02-02 |
2024-03-12 |
University Of Massachusetts |
Use of inverted terminal repeats (ITRS) from adeno-associated virus serotypes 8 and RH.39 in gene therapy vectors
|
US20240093189A1
(en)
|
2021-02-05 |
2024-03-21 |
Maze Therapeutics, Inc. |
Vectors comprising stuffer polynucleotide sequences
|
WO2022173847A2
(en)
*
|
2021-02-09 |
2022-08-18 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
KR20230145386A
(en)
|
2021-02-10 |
2023-10-17 |
리젠엑스바이오 인크. |
Treatment of mucopolysaccharidosis II using recombinant human iduronate-2-sulfatase (IDS)
|
JP2024509792A
(en)
|
2021-02-26 |
2024-03-05 |
武田薬品工業株式会社 |
Compositions and methods for the treatment of Fabry disease
|
WO2022187473A2
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
WO2022187548A1
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
CA3212876A1
(en)
|
2021-03-19 |
2022-09-22 |
Adrenas Therapeutics, Inc. |
Gene therapies for 21-hydroxylase deficiency
|
WO2022208342A1
(en)
|
2021-04-01 |
2022-10-06 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
CA3218333A1
(en)
|
2021-04-05 |
2022-10-13 |
Solid Biosciences Inc. |
Recombinant herpesvirales vector
|
AU2022258312A1
(en)
|
2021-04-12 |
2023-10-26 |
The Trustees Of The University Of Pennsylvania |
Compositions useful for treating spinal and bulbar muscular atrophy (sbma)
|
CA3216146A1
(en)
|
2021-04-23 |
2022-10-27 |
Douglas Anderson |
Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment
|
AU2022262771A1
(en)
|
2021-04-23 |
2023-11-02 |
The Trustees Of The University Of Pennsylvania |
Novel compositions with brain-specific targeting motifs and compositions containing same
|
CN117377500A
(en)
|
2021-04-26 |
2024-01-09 |
阿雷克森国际制药有限公司 |
Adeno-associated viral vector capsids with improved tissue tropism
|
KR20240004564A
(en)
|
2021-04-26 |
2024-01-11 |
리젠엑스바이오 인크. |
Administration of microdystrophin gene therapy for the treatment of dystrophinopathy
|
WO2022235614A2
(en)
|
2021-05-04 |
2022-11-10 |
Regenxbio Inc. |
Novel aav vectors and methods and uses thereof
|
WO2022241030A1
(en)
|
2021-05-11 |
2022-11-17 |
Regenxbio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
US20230056226A1
(en)
*
|
2021-06-08 |
2023-02-23 |
Nf2 Therapeutics, Inc. |
Compositions and methods for treating neurofibromatic disorders
|
CA3222911A1
(en)
*
|
2021-06-18 |
2022-12-22 |
Dyno Therapeutics, Inc. |
Capsid variants and methods of using the same
|
WO2022269466A1
(en)
|
2021-06-22 |
2022-12-29 |
Pfizer Inc. |
Production of adeno-associated virus vector in insect cells
|
WO2022272056A2
(en)
*
|
2021-06-24 |
2022-12-29 |
University Of Utah Research Foundation |
Compositions and methods for treating pgm1 deficiency
|
AU2022301302A1
(en)
|
2021-07-01 |
2024-01-25 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
TW202317768A
(en)
|
2021-07-08 |
2023-05-01 |
美商特納亞治療股份有限公司 |
Optimized expression cassettes for gene therapy
|
WO2023004331A1
(en)
|
2021-07-19 |
2023-01-26 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
WO2023004407A2
(en)
*
|
2021-07-23 |
2023-01-26 |
Duke University |
Adeno-associated virus compositions and methods of use thereof
|
CN117794561A
(en)
|
2021-07-30 |
2024-03-29 |
宫崎彻 |
Therapeutic agent for ischemic disease
|
WO2023019229A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified primary cells for allogeneic cell therapy
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
WO2023019227A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
WO2023019226A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
TW202330929A
(en)
*
|
2021-08-25 |
2023-08-01 |
美商北海康成製藥有限公司 |
Aav particles comprising a liver-tropic capsid protein and alpha-galactosidase and their use to treat fabry disease
|
WO2023028567A2
(en)
*
|
2021-08-25 |
2023-03-02 |
Canbridge Pharmaceuticals, Inc. |
Aav particles comprising a liver-tropic capsid protein and acid alpha-glucosidase (gaa) and their use to treat pompe disease
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
JP7175044B1
(en)
|
2021-09-24 |
2022-11-18 |
株式会社中山事務所 |
wave power generator
|
WO2023056329A1
(en)
|
2021-09-30 |
2023-04-06 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
TW202325845A
(en)
|
2021-10-02 |
2023-07-01 |
賓州大學委員會 |
Novel aav capsids and compositions containing same
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023060269A1
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
WO2023060248A1
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of p53-mediated cancers
|
WO2023060221A2
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of proteopathies
|
TW202333776A
(en)
|
2021-10-12 |
2023-09-01 |
美商阿斯帕醫療公司 |
Methods and compositions for treating leukodystrophies
|
US20230277600A1
(en)
|
2021-10-20 |
2023-09-07 |
University Of Rochester |
Treatment Of Age-Related White Matter Loss By Competitive Replacement Of Glial Cells
|
WO2023077092A1
(en)
|
2021-10-28 |
2023-05-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
TW202334436A
(en)
|
2021-11-02 |
2023-09-01 |
美商航海家醫療公司 |
Aav capsid variants and uses thereof
|
WO2023081633A1
(en)
|
2021-11-02 |
2023-05-11 |
University Of Rochester |
Tcf7l2 mediated remyelination in the brain
|
WO2023087019A2
(en)
|
2021-11-15 |
2023-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
WO2023091948A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023091949A2
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
WO2023102517A1
(en)
|
2021-12-02 |
2023-06-08 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
WO2023114897A2
(en)
*
|
2021-12-15 |
2023-06-22 |
Homology Medicines, Inc. |
Methods and compositions for the production of adeno-associated virus
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023133584A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of metachromatic leukodystrophy
|
WO2023133574A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for treatment of c9orf72-mediated disorders
|
WO2023135316A1
(en)
|
2022-01-17 |
2023-07-20 |
Dinaqor Ag |
Gene therapy composition and treatment for dystrophin-related cardiomyopathy
|
EP4215614A1
(en)
|
2022-01-24 |
2023-07-26 |
Dynacure |
Combination therapy for dystrophin-related diseases
|
WO2023147304A1
(en)
|
2022-01-25 |
2023-08-03 |
The Trustees Of The University Of Pennsylvania |
Aav capsids for improved heart transduction and detargeting of liver
|
WO2023147374A2
(en)
|
2022-01-25 |
2023-08-03 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
TW202342525A
(en)
|
2022-02-02 |
2023-11-01 |
美商阿科奧斯公司 |
Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
|
TW202346599A
(en)
|
2022-02-08 |
2023-12-01 |
美商航海家醫療公司 |
Aav capsid variants and uses thereof
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023164545A1
(en)
|
2022-02-23 |
2023-08-31 |
Massachusetts Institute Of Technology |
Methods for upregulating shank3 expression
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
TW202346590A
(en)
|
2022-03-13 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
Modified muscle-specific promoters
|
WO2023178220A1
(en)
|
2022-03-16 |
2023-09-21 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
WO2023183623A1
(en)
|
2022-03-25 |
2023-09-28 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
WO2023187728A1
(en)
|
2022-04-01 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
Gene therapy for diseases with cns manifestations
|
WO2023196842A1
(en)
|
2022-04-06 |
2023-10-12 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
WO2023196873A1
(en)
|
2022-04-06 |
2023-10-12 |
Regenxbio Inc. |
Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene forsuprachoidal administration
|
WO2023196892A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
WO2023196893A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
|
TW202345913A
(en)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
Formulations for suprachoroidal administration such as gel formulations
|
WO2023201207A1
(en)
|
2022-04-11 |
2023-10-19 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
WO2023198652A1
(en)
|
2022-04-11 |
2023-10-19 |
Centre National De La Recherche Scientifique |
Chemically-modified adeno-associated viruses
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023201308A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
WO2023205610A2
(en)
|
2022-04-18 |
2023-10-26 |
Regenxbio Inc. |
Hybrid aav capsids
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
WO2023215806A2
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
WO2023215807A1
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023230409A1
(en)
*
|
2022-05-24 |
2023-11-30 |
Kate Therapeutics, Inc. |
Compositions for treating xlmtm
|
WO2023235791A1
(en)
|
2022-06-02 |
2023-12-07 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023240158A2
(en)
*
|
2022-06-07 |
2023-12-14 |
Oregon Health & Science University |
Mutant adeno-associated virus (aav) capsids
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
WO2024006741A1
(en)
|
2022-06-28 |
2024-01-04 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024011112A1
(en)
|
2022-07-06 |
2024-01-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
WO2024044725A2
(en)
|
2022-08-24 |
2024-02-29 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
WO2024042485A1
(en)
|
2022-08-25 |
2024-02-29 |
Takeda Pharmaceutical Company Limited |
Composition for use in the treatment of fabry disease
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
WO2024064856A1
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of cardiomyopathy with aav gene therapy vectors
|
WO2024064863A2
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
|
WO2024073669A1
(en)
|
2022-09-30 |
2024-04-04 |
Regenxbio Inc. |
Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
|